Lupin inks 5-year-pact with LG Life to launch diabetes drug in India

As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM.<br />

hidden August 07, 2014 08:11:05 IST
Lupin inks 5-year-pact with LG Life to launch diabetes drug in India

Drug major Lupin has inked a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India.

As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM.

"According to the agreement, Lupin would be responsible for marketing and sales of BasugineTM in India," Lupin Ltd said in a statement.

Lupin inks 5yearpact with LG Life to launch diabetes drug in India

Image from Lupin

Insulin Glargine is indicated for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus.

Commenting on the development, Lupin Group President, India Region Formulations, Shakti Chakraborty said: "I believe that our entry into the insulin analogue market with launch of BasugineTM is a step in the right direction."

Lupin's foray in this segment will help the company further strengthen its diabetes portfolio enabling it to grow deeper into the segment and fuel growth in the years to come, he added.

According to IMS MAT data, the overall diabetes market size within the Indian pharmaceutical Market (IPM) stood at Rs 6,032 crore, growing at 18 per cent year-on-year.

The total insulin analogue market size is valued at Rs 585 crore with three year CAGR of 24 per cent while the total Glargine molecule market is estimated to be around Rs 218.5 crore.

Lupin's shares were trading 0.17 per cent down at Rs 1,175.45 apiece during afternoon trade on the BSE.

PTI

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines
India

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines

Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."

Mother’s psychological wellbeing during pregnancy benefits child’s future health, study reveals
Health

Mother’s psychological wellbeing during pregnancy benefits child’s future health, study reveals

The results of the study showed that maternal stress significantly predicted shorter telomeres in the offspring, while positivity predicted longer telomeres.

Obstructive sleep apnea patients more likely to suffer severe symptoms due to COVID-19 infection
Health

Obstructive sleep apnea patients more likely to suffer severe symptoms due to COVID-19 infection

The US National Sleep Foundation defines sleep apnea as a type of sleep disorder that is marked by abnormal breathing.